These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29210147)

  • 1. Drug exposure and the risk of multiple sclerosis: A systematic review.
    Yong HY; McKay KA; Daley CGJ; Tremlett H
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):133-139. PubMed ID: 29210147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
    Cruz Fernández-Espartero M; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
    Semin Arthritis Rheum; 2011 Dec; 41(3):524-33. PubMed ID: 22152489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cataract and glaucoma in patients with multiple sclerosis.
    Bazelier MT; Mueller-Schotte S; Leufkens HG; Uitdehaag BM; van Staa T; de Vries F
    Mult Scler; 2012 May; 18(5):628-38. PubMed ID: 22025330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.
    Chen Y; Sun J; Yang Y; Huang Y; Liu G
    Clin Rheumatol; 2016 Jan; 35(1):1-18. PubMed ID: 26573205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
    Fernández-Espartero MC; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
    Semin Arthritis Rheum; 2011 Feb; 40(4):330-7. PubMed ID: 20864146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
    Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
    Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
    Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of fracture in incident multiple sclerosis patients: the Danish National Health Registers.
    Bazelier MT; Bentzen J; Vestergaard P; Stenager E; Leufkens HG; van Staa TP; de Vries F
    Mult Scler; 2012 Nov; 18(11):1609-16. PubMed ID: 22472998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset of multiple sclerosis associated with anti-TNF therapy.
    Sicotte NL; Voskuhl RR
    Neurology; 2001 Nov; 57(10):1885-8. PubMed ID: 11723281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
    Pfueller CF; Seipelt E; Zipp F; Paul F
    Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Bonovas S; Minozzi S; Lytras T; González-Lorenzo M; Pecoraro V; Colombo S; Polloni I; Moja L; Cinquini M; Marino V; Goletti D; Matucci A; Tocci G; Milano GM; Scarpa R; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):35-54. PubMed ID: 27924644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.
    Barnabe C; Martin BJ; Ghali WA
    Arthritis Care Res (Hoboken); 2011 Apr; 63(4):522-9. PubMed ID: 20957658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
    Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
    Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis.
    Alonso A; Jick SS; Hernán MA
    Neurology; 2006 Feb; 66(4):572-5. PubMed ID: 16505314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
    Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
    Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.